This company listing is no longer active
このページの翻訳は実験的なもので、現在開発中です。お待ちしております
OKYO Pharma 過去の業績
過去 基準チェック /06
OKYO Pharma has been growing earnings at an average annual rate of 39.4%, while the Biotechs industry saw earnings growing at 7.2% annually.
主要情報
39.4%
収益成長率
62.4%
EPS成長率
Biotechs 業界の成長 | 11.5% |
収益成長率 | n/a |
株主資本利益率 | n/a |
ネット・マージン | n/a |
前回の決算情報 | 30 Sep 2022 |
最近の業績更新
更新なし
Recent updates
Can OKYO Pharma (LON:OKYO) Afford To Invest In Growth?
Nov 26Is OKYO Pharma (LON:OKYO) In A Good Position To Deliver On Growth Plans?
Jan 27Here's Why We're Not At All Concerned With OKYO Pharma's (LON:OKYO) Cash Burn Situation
Sep 22We Think OKYO Pharma (LON:OKYO) Can Easily Afford To Drive Business Growth
Mar 17We're Interested To See How OKYO Pharma (LON:OKYO) Uses Its Cash Hoard To Grow
Dec 02収支内訳
OKYO Pharma の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。
収益と収入の歴史
日付 | 収益 | 収益 | G+A経費 | 研究開発費 |
---|---|---|---|---|
30 Sep 22 | 0 | -7 | 0 | 3 |
30 Jun 22 | 0 | -5 | 0 | 2 |
31 Mar 22 | 0 | -4 | 0 | 1 |
31 Dec 21 | 0 | -4 | 0 | 1 |
30 Sep 21 | 0 | -4 | 0 | 0 |
30 Jun 21 | 0 | -3 | 0 | 0 |
31 Mar 21 | 0 | -3 | 0 | 0 |
31 Dec 20 | 0 | -1 | 0 | 0 |
30 Sep 20 | 0 | 0 | 0 | 0 |
30 Jun 20 | 0 | -1 | 0 | 0 |
31 Mar 20 | 0 | -1 | 0 | 0 |
31 Dec 19 | 0 | -3 | 0 | 1 |
30 Sep 19 | 0 | -4 | 0 | 2 |
30 Jun 19 | 0 | -4 | 0 | 2 |
31 Mar 19 | 0 | -4 | 0 | 2 |
31 Dec 18 | 0 | -3 | 0 | 1 |
30 Sep 18 | 0 | -2 | 0 | 1 |
30 Jun 18 | 0 | -11 | 0 | 1 |
31 Mar 18 | 0 | -20 | 0 | 0 |
31 Dec 17 | 0 | -20 | 0 | 0 |
30 Sep 17 | 0 | -19 | 0 | 0 |
30 Jun 17 | 0 | -10 | 0 | 0 |
31 Mar 17 | 0 | 0 | 0 | 0 |
31 Dec 16 | 0 | 0 | 0 | 0 |
30 Sep 16 | 0 | 0 | 1 | 0 |
質の高い収益: OKYO is currently unprofitable.
利益率の向上: OKYO is currently unprofitable.
フリー・キャッシュフローと収益の比較
過去の収益成長分析
収益動向: OKYO is unprofitable, but has reduced losses over the past 5 years at a rate of 39.4% per year.
成長の加速: Unable to compare OKYO's earnings growth over the past year to its 5-year average as it is currently unprofitable
収益対業界: OKYO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-7%).
株主資本利益率
高いROE: OKYO's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.